PLUR
Pluri, Inc.
NASDAQ · Healthcare · Biotechnology · IL
$1.23
−3.15%Oct 30, 2026, 13:14 UTC
Pluri Inc. entered into securities purchase agreements to sell 909,092 common shares at US$1.10 per share and warrants to purchase up to 909,092 additional shares at US$1.30 per share, for total proceeds of US$1 million; the offering was expected to close by October 30, 2026.
Oct 26, 2026, 11:03 UTC
ZEO ScientifiX, Inc. and Pluri Inc. entered into a definitive strategic agreement to expand their U.S. manufacturing and commercialization platform for regenerative medicine, aesthetics, wellness, and longevity markets.
Source:Aug 27, 2026, 12:00 UTC
Pluri Inc. priced a registered direct offering and concurrent private placement of 2,228,940 common shares at $1.50 per share to a single healthcare-focused institutional investor, expecting gross proceeds of approximately $3.3 million.
Source:Jul 28, 2026, 12:00 UTC
Pluri Inc.'s subsidiary Cellav completed cosmetic regulatory registration in the UK for its regenerative aesthetics product Regenativo+.
Source: